CVS chief: employer plans won’t cover GLP-1 weight-loss drugs yet
TL;DR
CVS Health’s CEO David Joyner says private employers aren’t ready to broadly cover GLP-1 weight-loss drugs like Ozempic because of high costs and uncertain long-term savings; prices need to come down and there must be clear evidence they reduce overall health care costs before broader coverage resumes, even as Medicare moves to cover GLP-1s.
Topics:businesshealth#cvs-health-corp#health#health-care-costs#health-insurance-providers#insurance-industry#prescription-drugs
- Why your health plan doesn’t cover GLP-1s, according to a top insurance exec The Washington Post
- Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs — many are finding ways around it CNBC
- Trouble getting weight loss drugs covered by insurance? Here’s what to know Daytona Times
- Pharmacists Can Help Patients Navigate GLP-1 Access, Affordability, and Long-Term Use Pharmacy Times – Pharmacy Practice News and Expert Insights
- Some employers steer workers toward cash platforms for GLP-1 obesity drugs Managed Healthcare Executive
Want the full story? Read the original reporting
Read on The Washington Post